Reimbursement Review Reports


( Last Updated : April 2, 2015)

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Recommendation Type Sort descending Project Status Date Submission Received Date Recommendation Issued
Effient Prasugrel Acute coronary syndrome Do not list Complete
Fampyra Fampridine Multiple sclerosis, improve walking disability Do not list Complete
Sublinox Zolpidem tartrate Insomnia Do not list Complete
Abilify Aripiprazole Depression, Major Depressive Disorder Do not list Complete
Elelyso Taliglucerase alfa Gaucher disease Do not list Complete
Otezla Apremilast Plaque psoriasis Do not list Complete
Dymista Azelastine HCl and fluticasone propionate Seasonal allergic rhinitis Do not list Complete
Fabrazyme Agalsidase beta Fabry Disease Do not list Complete
Lyrica Pregabalin Pain, Neuropathic Do not list Complete
NovoMix 30 Insulin aspart/insulin aspart protamine Diabetes mellitus Do not list Complete